EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan. The options allow the purchase of up to 15,000 shares of EyePoint Pharmaceuticals common stock at an exercise price of $6.69 per share. The options have a ten-year term and vest over four years, subject to the employee’s continued service with the company.
11/16/2023 - 07:00 AM
WATERTOWN, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 15,000 shares of EyePoint Pharmaceuticals common stock to five new employees. The stock options were granted on November 15, 2023. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $6.69 per share, the closing price of EyePoint Pharmaceuticals’ common stock on November 15, 2023. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint Pharmaceuticals through the applicable vesting dates.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit www.eyepointpharma.com .
For EyePoint Pharmaceuticals:
Investors: Christina Tartaglia Stern IR Direct: 212-698-8700christina.tartaglia@sternir.com
Media Contact: Amy Phillips Green Room Communications Direct: 412-327-9499aphillips@greenroompr.com
The stock options were granted as inducement awards to new employees outside the Company’s 2023 Long-Term Incentive Plan.
Up to an aggregate of 15,000 shares of EyePoint Pharmaceuticals common stock can be purchased through the stock options.
The exercise price of the stock options is $6.69 per share.
The stock options have a ten-year term.
The stock options vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years.
EyePoint Pharmaceuticals Inc
EYPT Rankings
#1302 Ranked by Stock Gains
EYPT Stock Data
Industry
Analytical Laboratory Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Analytical Laboratory Instrument Manufacturing
About EYPT
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®